ReviewJournal of the American Society of Nephrology : JASN2025
Questions and Caveats in Antigen-Defined Membranous Nephropathy.
Review in Journal of the American Society of Nephrology : JASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multicentre comparative study of neural epidermal growth factor-like 1 proteinWorld journal of nephrology · 2026Article
- Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies.Frontiers in immunology · 2026Review
- Contemporary review of primary membranous nephropathy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Remarkable progress has been made in the discovery of autoantigens in membranous nephropathy. With increasing testing for membranous antigens in daily practice, it is important to consider the varying strength of associations between certain antigens and underlying conditions. This review explores questions and caveats that arise when assessing results of membranous antigen testing. Specifically, we will discuss: ( 1 ) discrepancy between tissue antigen and clinical scenario, focusing on phospholipase A2 receptor; ( 2 ) one antigen≠one clinical condition, i.e ., the heterogeneity of membranous antigens seen in one clinical condition (such as in sarcoidosis), and conversely, heterogeneity of conditions associated with one antigen (such as for neural epidermal growth factor-like 1); ( 3 ) rare presence of multiple membranous-associated antigens in tissue or blood (such as with antiprotocadherin 7); and ( 4 ) lupus membranous nephritis-related antigens and their influence on diagnosis or treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.